Research and Development
Martin Mackay, Ph.D., Executive Vice President, Global Head of Research & Development
Alexion’s research and development programs are focused on highly innovative therapies with the potential to transform the lives of patients with severe and life-threatening rare disorders for which there are no effective treatment options. Scientists at Alexion are working relentlessly to understand the underlying causes of these diseases and develop breakthrough medicines to treat them.
Soliris® (eculizumab) is a prime example of Alexion’s R&D capabilities and commitment to breakthrough medical innovation. Alexion discovered and developed this first-in-class terminal complement inhibitor from the laboratory through regulatory approval and commercialization. Today, Soliris is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation.
Alexion’s current development programs span several therapeutic areas, including hematology, nephrology, transplant, neurology, metabolic disorders and inflammatory disorders.